ERBB2 and neoplasm: For example, patients with TP53 and ERBB2 (HER2) mutations have a higher risk of tumor recurrence and progression.[4] Furthermore, significant disparities are observed among different racial groups, such as the variations in survival outcomes and genomic profiles.[5] To comprehensively understand the biological implications of common mutations, conduct region‐specific research, and facilitate the development of precise, personalized treatment methods, it is imperative to establish dependable personalized models that closely resemble the original tumor.